AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aptevo Therapeutics Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG009RRZ8D1
1.61▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
1.61
Day's Range
1.60 – 1.64
52-Week Range
0.50 – 10.77
Volume
7,124
Avg Volume
48.7K
Share Statistics
Shares Outstanding
Employees
33
Exchange
XNAS
Listed
2016-07-20
Share count as of August 14, 2026

Aptevo Therapeutics Inc (APVO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aptevo Therapeutics Inc (APVO)
What is Aptevo Therapeutics Inc's Market Cap?
Aptevo Therapeutics Inc's Market Cap is $2.9M, based on as-reported figures from SEC (XBRL) filings.
What is Aptevo Therapeutics Inc's Net Income (TTM)?
Aptevo Therapeutics Inc's Net Income (TTM) is -$26.4M, based on as-reported figures from SEC (XBRL) filings.
What is Aptevo Therapeutics Inc's EBITDA?
Aptevo Therapeutics Inc's EBITDA is -$26.7M, based on as-reported figures from SEC (XBRL) filings.
What is Aptevo Therapeutics Inc's Diluted EPS (TTM)?
Aptevo Therapeutics Inc's Diluted EPS (TTM) is -14.66, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · APVOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Loss from operations
Other income:
Other income, net
Net loss
Dividend attributable to down round feature of warrants—
Net loss attributable to common stockholders
Basic net loss per share—
Diluted net loss per share—